All Stories

  1. Peptide Amphiphiles for Pharmaceutical Applications

    Article • Current Medicinal Chemistry, April 2024, Bentham Science Publishers

    Dr Isabel Haro

  2. Nanotechnology-Based Platforms for Vaginal Delivery of Peptide Microbicides

    Article • Current Medicinal Chemistry, August 2021, Bentham Science Publishers

    Dr Isabel Haro

  3. Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis

    Article • PLoS ONE, May 2019, PLOS

    Dr Isabel Haro

  4. Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), August 2017, De Gruyter

    Dr Isabel Haro

  5. A study of HIV-1 FP inhibition by GBV-C peptides using lipid nano-assemblies

    Article • Colloids and Surfaces A Physicochemical and Engineering Aspects, September 2015, Elsevier

    Dr Isabel Haro

  6. The Use of Citrullinated Peptides for the Diagnosis and Prognosis of Rheumatoid Arthritis

    Article • Current Topics in Medicinal Chemistry, January 2015, Bentham Science Publishers

    Dr Isabel Haro

  7. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery

    Article • International Journal of Nanomedicine, January 2015, Taylor & Francis

    Dr Isabel Haro, M LUISA GARCÍA

  8. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1

    Article • European Journal of Medicinal Chemistry, October 2014, Elsevier

    Dr Isabel Haro

  9. Updating the Use of Synthetic Peptides as Inhibitors of HIV-1 Entry

    Article • Current Medicinal Chemistry, March 2014, Bentham Science Publishers

    Dr Isabel Haro

  10. HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds

    Article • Current Medicinal Chemistry, December 2013, Bentham Science Publishers

    Dr Isabel Haro

  11. Editorial (Hot Topic:Rheumatoid Arthritis: Current Advances in Pathogenesis, Diagnosis and Therapy)

    Article • Current Topics in Medicinal Chemistry, April 2013, Bentham Science Publishers

    Dr Isabel Haro

  12. Citrullinated Peptides in the Diagnosis of Rheumatoid Arthritis

    Article • Current Topics in Medicinal Chemistry, April 2013, Bentham Science Publishers

    Dr Isabel Haro

  13. Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and –negative rheumatoid arthritis patients

    Article • Arthritis Research & Therapy, January 2013, Springer Science + Business Media

    Dr Isabel Haro

  14. Design and application of GB virus C (GBV-C) peptide microarrays for diagnosis of GBV-C/HIV-1 co-infection

    Article • Fresenius Journal of Analytical Chemistry, December 2012, Springer Science + Business Media

    Dr Isabel Haro

  15. Oligonucleotide-Peptide Conjugates: Solid-Phase Synthesis under Acidic Conditions and Use in ELISA Assays

    Article • Molecules, November 2012, MDPI AG

    Dr Isabel Haro, Ramon Eritja

  16. Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: Interaction with model membranes

    Article • International Journal of Pharmaceutics, October 2012, Elsevier

    Dr Isabel Haro

  17. Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?

    Article • Clinical Rheumatology, March 2012, Springer Science + Business Media

    Dr Isabel Haro

  18. Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection

    Article • Journal of Peptide Science, March 2012, Wiley

    Dr Isabel Haro

  19. The Use of Chimeric Vimentin Citrullinated Peptides for the Diagnosis of Rheumatoid Arthritis

    Article • Journal of Medicinal Chemistry, November 2011, American Chemical Society (ACS)

    Dr Isabel Haro

  20. Biophysical Investigations of GBV-C E1 Peptides as Potential Inhibitors of HIV-1 Fusion Peptide

    Article • ChemPhysChem, September 2011, Wiley

    Dr Isabel Haro

  21. Carbon nanotube composite peptide-based biosensors as putative diagnostic tools for rheumatoid arthritis

    Article • Biosensors and Bioelectronics, September 2011, Elsevier

    Dr Isabel Haro

  22. Effect of E1(64–81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models

    Article • Biochimica et Biophysica Acta (BBA) - Biomembranes, September 2011, Elsevier

    Dr Isabel Haro

  23. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C

    Article • Journal of Colloid and Interface Science, August 2011, Elsevier

    Dr Isabel Haro

  24. Diagnostic Value of Anti-GBV-C Antibodies in HIV-Infected Patients

    Article • Chemical Biology & Drug Design, June 2011, Wiley

    Dr Isabel Haro

  25. Antibodies against β-fibrin synthetic peptides: A study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients

    Article • European Journal of Medicinal Chemistry, April 2011, Elsevier

    Dr Isabel Haro

  26. Synthesis of a New Series of Enkaphalin Related Galactosyl Conjugates

    Article • Bulletin des Sociétés Chimiques Belges, September 2010, Wiley

    Dr Isabel Haro

  27. Effect of Synthetic Peptides Belonging to E2 Envelope Protein of GB Virus C on Human Immunodeficiency Virus Type 1 Infection

    Article • Journal of Medicinal Chemistry, August 2010, American Chemical Society (ACS)

    Dr Isabel Haro

  28. A Langmuir Monolayer Study of the Interaction of E1(145−162) Hepatitis G Virus Peptide with Phospholipid Membranes

    Article • The Journal of Physical Chemistry B, January 2010, American Chemical Society (ACS)

    Dr Isabel Haro

  29. Assessment of synthetic chimeric multiple antigenic peptides for diagnosis of GB virus C infection

    Article • Analytical Biochemistry, January 2010, Elsevier

    Dr Isabel Haro

  30. Synthetic Peptides of Hepatitis G Virus (GBV-C/HGV) in the Selection of Putative Peptide Inhibitors of the HIV-1 Fusion Peptide

    Article • The Journal of Physical Chemistry B, May 2009, American Chemical Society (ACS)

    Dr Isabel Haro

  31. Behaviour of a peptide sequence from the GB virus C/hepatitis G virus E2 protein in Langmuir monolayers: Its interaction with phospholipid membrane models

    Article • Biophysical Chemistry, May 2009, Elsevier

    Dr Isabel Haro

  32. Fluorescence study of the dynamic interaction between E1(145–162) sequence of hepatitis GB virus C and liposomes

    Article • Fresenius Journal of Analytical Chemistry, January 2009, Springer Science + Business Media

    Dr Isabel Haro

  33. Synthesis and biological activity of substance P analogues

    Article • International journal of peptide & protein research, January 2009, Wiley

    Dr Isabel Haro

  34. Interaction of GB Virus C/Hepatitis G Virus Synthetic Peptides with Lipid Langmuir Monolayers and Large Unilamellar Vesicles

    Article • The Journal of Physical Chemistry B, January 2009, American Chemical Society (ACS)

    Dr Isabel Haro

  35. Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

    Article • Arthritis Research & Therapy, January 2009, Springer Science + Business Media

    Dr Isabel Haro

  36. Peptide-Based Diagnostic Assays

    Article • December 2008, Taylor & Francis

    Dr Isabel Haro

  37. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage

    Article • Biophysical Chemistry, January 2008, Elsevier

    Dr Isabel Haro

  38. Antibodies to Citrullinated Human Fibrinogen Synthetic Peptides in Diagnosing Rheumatoid Arthritis

    Article • Journal of Medicinal Chemistry, July 2007, American Chemical Society (ACS)

    Dr Isabel Haro

  39. Synthesis of Overlapping Fibrin Citrullinated Peptides and their use for Diagnosing Rheumatoid Arthritis

    Article • Chemical Biology & Drug Design, October 2006, Wiley

    Dr Isabel Haro

  40. Interfacial Properties of a Synthetic Peptide Derived from Hepatitis G Virus E2 Protein:  Interaction with Lipid Monolayers

    Article • Langmuir, January 2006, American Chemical Society (ACS)

    Dr Isabel Haro

  41. Characterization of a putative fusogenic sequence in the E2 hepatitis G virus protein

    Article • Archives of Biochemistry and Biophysics, October 2005, Elsevier

    Dr Isabel Haro

  42. Interaction of synthetic peptides corresponding to hepatitis G virus (HGV/GBV-C) E2 structural protein with phospholipid vesicles

    Article • European Journal of Biochemistry, April 2005, Wiley

    Dr Isabel Haro

  43. Perturbations induced by synthetic peptides from hepatitis G virus structural proteins in lipid model membranes: a fluorescent approach

    Article • Luminescence, January 2005, Wiley

    Dr Isabel Haro

  44. Analysis of the effect of a peptide sequence of the E2 protein (HGV/GBV-C) on the physicochemical properties of zwitterionic and negatively charged bilayers

    Article • Luminescence, January 2005, Wiley

    Dr Isabel Haro

  45. Design of Synthetic Peptidic Constructs for the Vaccine Development Against Viral Infections

    Article • Current Protein and Peptide Science, December 2004, Bentham Science Publishers

    Dr Isabel Haro

  46. Effects of Overlapping GB Virus C/Hepatitis G Virus Synthetic Peptides on Biomembrane Models

    Article • Langmuir, December 2004, American Chemical Society (ACS)

    Dr Isabel Haro

  47. Interaction of three β-interferon domains with liposomes and monolayers as model membranes

    Article • Biophysical Chemistry, October 2004, Elsevier

    Dr Isabel Haro

  48. Study in mono and bilayers of the interaction of hepatitis G virus (GBV-C/HGV) synthetic antigen E2(99-118) with cell membrane phospholipids

    Article • Biophysical Chemistry, June 2004, Elsevier

    Dr Isabel Haro

  49. Interaction of Antimicrobial Arginine-Based Cationic Surfactants with Liposomes and Lipid Monolayers

    Article • Langmuir, April 2004, American Chemical Society (ACS)

    Dr Isabel Haro

  50. Peptides and Liposomes: From Biophysical to Immunogenic Studies

    Article • Current Drug Targets, November 2003, Bentham Science Publishers

    Dr Isabel Haro

  51. GB Virus C (GBV-C) / Hepatitis G Virus (HGV): Towards the Design of Synthetic Peptides-based Biosensors for Immunodiagnosis of GBV-C / HGV Infection

    Article • Current Protein and Peptide Science, August 2003, Bentham Science Publishers

    Dr Isabel Haro

  52. Liposome entrapment and immunogenic studies of a synthetic lipophilic multiple antigenic peptide bearing VP1 and VP3 domains of the hepatitis A virus: a robust method for vaccine design

    Article • FEBS Letters, March 2003, Wiley

    Dr Isabel Haro

  53. Miscibility of Hepatitis A Synthetic Antigen Peptides with Lipid Monolayers:  Effect of the Amino Acid Sequence Change

    Article • The Journal of Physical Chemistry B, January 2003, American Chemical Society (ACS)

    Dr Isabel Haro

  54. Synthesis and surface activity measurements of HGV NS3 (513–522) peptide and its palmitoyl derivative

    Article • Materials Science and Engineering C, December 2002, Elsevier

    Dr Isabel Haro

  55. Use of [Cit312,314] filaggrin (306–324) analogue for the diagnosis of rheumatoid arthritis. Conformational study by circular dichroism and fourier transformed infrared spectroscopy

    Article • November 2002, Springer Science + Business Media

    Dr Isabel Haro

  56. Interfacial Interactions of Hydrophobic Peptides with Lipid Bilayers

    Article • Journal of Colloid and Interface Science, February 2002, Elsevier

    Dr Isabel Haro

  57. Hydrophobic Laminin-Related Peptides: Synthesis and Surface Properties

    Article • Journal of Colloid and Interface Science, July 2001, Elsevier

    Dr Isabel Haro

  58. Phospholipid−Model Membrane Interactions with Branched Polypeptide Conjugates of a Hepatitis a Virus Peptide Epitope

    Article • Bioconjugate Chemistry, January 2000, American Chemical Society (ACS)

    Dr Isabel Haro

  59. Enhancement of the immunogenicity of a synthetic peptide bearing a VP3 epitope of hepatitis A virus

    Article • FEBS Letters, October 1998, Wiley

    Dr Isabel Haro

  60. Conformational behavior of the HAV-VP3(110–121) peptidic sequence and synthetic analogs in membrane environments studied by CD and computational methods

    Article • Biopolymers, June 1998, Wiley

    Dr Isabel Haro

  61. Conformational behavior of the HAV‐VP3(110–121) peptidic sequence and synthetic analogs in membrane environments studied by CD and computational methods

    Article • Biopolymers, June 1998, Wiley

    Dr Isabel Haro

  62. A new continuous epitope of hepatitis A virus

    Article • Journal of Medical Virology, February 1998, Wiley

    Dr Isabel Haro

  63. Physicochemical study of laminin-related peptides

    Article • Supramolecular Science, September 1997, Elsevier

    Dr Isabel Haro

  64. Interactions of a tetravalent branched peptide from VP3 capsid protein of hepatitis A virus with monolayers as biomembrane models

    Article • Supramolecular Science, September 1997, Elsevier

    Dr Isabel Haro

  65. Conformational study of the preferred conformations of the peptide sequence VP3(110–121) of HAV by circular dichroism and molecular mechanics

    Article • March 1997, Springer Science + Business Media

    Dr Isabel Haro

  66. Anti-Hepatitis A Virus Antibody Response Elicited in Mice by Different Forms of a Synthetic VP1 Peptide

    Article • Microbiology and Immunology, July 1995, Wiley

    Dr Isabel Haro

  67. Physicochemical study of hepatitis A and B peptide fragments with monolayers as membrane models

    Article • Journal of Colloid and Interface Science, August 1992, Elsevier

    Dr Isabel Haro

  68. Solid phase synthesis of potential antigenic peptides and new lipopeptides of hepatitis B virus

    Article • Journal of the Chemical Society Perkin Transactions 1, January 1991, Royal Society of Chemistry

    Dr Isabel Haro

  69. A Synthetic Glycopeptide of Substance P Analogue (SP6–11) with Enhanced NK-1 Receptor Specificity

    Article • Journal of Pharmaceutical Sciences, January 1990, Elsevier

    Dr Isabel Haro

  70. In vitro activity and selectivity of glucosidic SP(66-11) analogues

    Article • Pharmacology Biochemistry and Behavior, November 1989, Elsevier

    Dr Isabel Haro

  71. Hydrophobic peptides: Synthesis and interaction with model membranes

    Article • Springer Science + Business Media

    Dr Isabel Haro